BPC-157 is a synthetic 15-residue peptide discussed in preclinical cell and animal research. The cited studies and reviews cover nitric-oxide-system observations, tendon-cell behavior, skeletal-muscle-cell migration and central-nervous-system models; they do not establish human efficacy. The current wholesale price list contains two entries marked 5 / Injectable and 10 / Injectable, but it does not state the dosage unit. Confirm the counterion, fill amount, identity method and batch-specific handling data before ordering.
| Class | Synthetic 15-residue research peptide. |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. |
| Theoretical mass | Approximately 1419 Da; confirm the supplied counterion, water content and observed mass. |
| Listed presentations | 5 / Injectable and 10 / Injectable. The current wholesale price list does not state the dosage unit. |
| Batch quality | Verify identity, chromatographic area purity, net peptide content, related substances, water and residual solvents in current batch documents. |
| Handling | Use the storage, diluent and in-use window supplied for the allocated batch. No universal reconstitution window is asserted. |
Wholesale from $1.80
Published wholesale tiers apply when the order reaches 100+ total units; the tier is selected by quantity of each SKU. Smaller total orders are quoted separately.
| SKU / form | 10–24 units of this SKU | 25–49 units of this SKU | 50+ units of this SKU |
|---|---|---|---|
| 10 / Injectable | $4.76 | $4.17 | $3.57 |
| 5 / Injectable | $2.40 | $2.10 | $1.80 |
The price list identifies two BPC-157 presentations, but it does not give the dosage unit or batch specification. Resolve those details before comparing quotes or protocols.
Confirm the dosage unit, fill amount, sequence, counterion or salt form, vial presentation and observed mass for each quoted SKU.
Request the analytical method, chromatographic area purity, net peptide content, related substances, water and residual-solvent results for the allocated lot.
Match the supplied form, diluent, storage conditions and in-use window to the exact cell or animal protocol. Do not infer handling from a different formulation.
Published studies describe specific experimental material and models. They do not verify the identity, purity, stability or performance of an independently supplied batch.
Sikiric et al. (2014). Stable Gastric Pentadecapeptide BPC 157-NO-system Relation. Current Pharmaceutical Design. DOI: 10.2174/13816128113190990411
Study scope: Experimental cell and animal models discussed across the review; no human efficacy population. BPC 157 used across heterogeneous experimental preparations, routes and doses.
What it supports: Supports a bounded discussion of reported BPC 157 interactions with the nitric-oxide system in preclinical research.
Boundary: This is not a human efficacy trial. It does not support a general healing claim, a fixed dose or route, or equivalence with a supplier batch.
Vukojevic et al. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research. DOI: 10.4103/1673-5374.320969
Study scope: Central-nervous-system findings synthesized from preclinical models; no verified human treatment population. Experimental BPC 157 preparations used in the reviewed studies.
What it supports: Supports describing the existence and limits of preclinical central-nervous-system research on BPC 157.
Boundary: The review does not establish therapeutic efficacy in people and does not verify the composition or performance of independently sourced material.
Chang et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. DOI: 10.1152/japplphysiol.00945.2010
Study scope: Tendon outgrowth, survival and migration were examined in experimental tendon and tendon-cell models. BPC 157 as used in the study's defined experimental system.
What it supports: Supports discussion of tendon-cell outgrowth, survival and migration within the reported experimental model.
Boundary: The findings cannot be presented as evidence of human tendon healing, a clinical treatment effect or batch interchangeability.
Chang et al. (2014). Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. DOI: 10.3390/molecules191119066
Study scope: Tendon fibroblasts in a laboratory model. BPC 157 exposure under the study's cell-culture conditions.
What it supports: Supports a narrow statement about growth-hormone-receptor expression in the reported tendon-fibroblast model.
Boundary: A cell-culture signaling result does not establish whole-tissue healing, human efficacy or the performance of a commercial batch.
Wang (2019). BPC 157 Promotes Skeletal Muscle Cells Migration in Association with Up-regulation of Paxillin and Vinculin Expression. Rehabilitation Practice and Science. DOI: 10.6315/tjpmr.201906_47(1).0003
Study scope: Skeletal muscle cells in a migration assay. BPC 157 exposure under the study's cell-culture conditions.
What it supports: Supports a narrow statement about cell migration and paxillin/vinculin expression in the reported skeletal-muscle-cell model.
Boundary: The study does not demonstrate systemic tissue repair, human performance or clinical efficacy.
BPC-157 is a synthetic 15-residue peptide used in laboratory research. The cited evidence is preclinical and does not establish a human treatment effect.
The current wholesale price list contains 5 / Injectable and 10 / Injectable entries. The dosage unit is not stated, so it must be confirmed in the quote and batch documents.
Published tiers apply when the order reaches 100+ total units. The price tier is selected by quantity of each SKU: 10–24, 25–49 or 50+ units. The lowest listed tier is $1.80 for the 5 / Injectable presentation at 50+ units of that SKU.
No. The cited papers cover reviews, tendon-cell models and skeletal-muscle-cell assays. They do not establish human efficacy.
Confirm sequence identity, counterion or salt form, observed mass, chromatographic area purity, net peptide content, related substances, water, residual solvents and the supplied presentation.
Use the instructions issued for the allocated batch and formulation. This page does not publish a universal diluent, storage temperature or post-reconstitution window.